Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Association between cholecystectomy for gallstone disease and risk factors for c...
Journal Information
Vol. 11. Issue 1.
Pages 85-89 (January - February 2012)
Share
Share
Download PDF
More article options
Visits
706
Vol. 11. Issue 1.
Pages 85-89 (January - February 2012)
Open Access
Association between cholecystectomy for gallstone disease and risk factors for cardiovascular disease
Visits
706
Norberto C. Chavez-Tapia*, Ileana Mac Kinney-Novelo*, Sergio E. Sifuentes-RenterÍa*, Maximiliano Torres-Zavala*, Gildardo Castro-Gastelum*, Karla Sánchez-Lara*, Carla Paulin-Saucedo*, Misael Uribe*, Nahum Méndez-Sánchez
,
Corresponding author
nmendez@medicasur.org.mx

Correspondence and reprint:
* Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City
This item has received

Under a Creative Commons license
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (3)
Table 1. Characteristics of patients undergoing cholecystectomy and healthy controls.
Table 2. Risk factors and previous history of cardiovascular disease.
Table 3. Increased risk of cardiovascular disease risk factors in subjects undergoing cholecystectomy versus healthy controls.
Show moreShow less
Abstract

Objective. Gallbladder disease and cardiovascular disease share risk factors. Both have a great impact on the economics of health systems. There is evidence suggesting an increased risk of cardiovascular disease in patients with gallbladder disease, but the association of gallbladder disease with other risk factors for cardiovascular disease is unclear. The aim of this study is to analyse the relationship between cholecystectomy for gallstone disease and risk factors for cardiovascular disease.

Material and methods. This is a case-control study comparing subjects undergoing cholecystectomy with controls without gallbladder disease or cholecystectomy. Demographic, anthropometric, and biochemical data were recorded and risk factors for cardiovascular disease were assessed. The data were analysed with chi square test, student t test and logistic regression (univariate and multivariate).

Results. Seven hundred and ninety-eight subjects were included. The multivariate analyses demonstrated that, compared with controls, cases had an increased prevalence of metabolic risk factors for cardiovascular disease (odds ratio (OR) 2.8, 95% confidence interval (CI) 1.8-4.8, p = 0.001), including type 2 diabetes mellitus (OR 2.2, 95% CI 1.1-4.5, p = 0.018), high blood pressure (OR 5.1, 95% CI 2.6-10.1, p = 0.001), and high cholesterol levels (OR 2.7, 95% CI 1.3-5.5, p = 0.004). No differences were observed in the incidence of cardiovascular disease.

Conclusion. Patients undergoing cholecystectomy had an increased prevalence of risk factors for cardiovascular disease, independent of age, sex, or body mass index.

Key words:
Gallstones
Cardiovascular disease
Obesity
Full Text
Introduction

Gallstone disease (GD) and cardiovascular disease (CVD) are both considered public health problems and have increased in prevalence through time, especially in the Western world.12 CVD remains the leading cause of mortality worldwide. Approximately 33% of all deaths are caused by CVD, which includes type 2 diabetes mellitus (T2DM), coronary heart disease (CHD), cerebrovascular disease, and hypertension.3 In the United States, 800,000 cholecystectomies are performed every year; this affects the economy of the individual and also the economy of the public and private health systems.4 Currently, the pathogenesis of gallstones is well known: gallstone formation involves environmental, genetic, and organic factors, ethnicity, and dietary habits.57 More than 80% of gallstones are formed from cholesterol, as is atheroma.2 Based on the third US National Health and Nutrition Examination Survey (NHANES III), Ruhl & Everhart8 analysed data from 14,228 subjects in whom the prevalence of GD was 7.1% and of cholecystectomy 5.3%. Patients with GD had increased mortality for CVD (hazard risk = 1.4; 95% CI 1.2-1.7), which can be explained because both diseases share risk factors such as age, obesity, diabetes, and components of the metabolic syndrome.9

Recently we analysed the thickness of the intima and media layers of the carotid artery in patients with GD and found that 38.7% of these patients presented with an increased thickness of this artery compared with 20% of controls.10 In another study, patients with CHD had an increased risk of developing GD (OR = 2.84, 95% CI: 1.33-6.0, p < 0.007), the main associated factors being body mass index (BMI), waist circumference, and homeostatic model assessment-insulin resistance (HOMA-IR).9 Another study in patients with breast cancer found a high incidence of myocardial infarction in patients with GD.11 Little information has been published regarding the association between cholecystectomy for GD and risk factors for cardiovascular disease. Recently CVD, diabetes mellitus, and a history of cerebrovascular accident were reported as independent risk factors for acute cholecystitis.12 Despite the broad association between GD and CVD, there is no clear information regarding this relationship in subjects undergoing cholecystectomy.

Objective

To investigate the association between cholecystectomy for GD and risk factors for CVD.

Material and MethodsStudy population

We conducted a retrospective study in a private teaching hospital in Mexico City (Medica Sur Clinic & Foundation). Three hundred and ninety-nine patients who underwent cholecystectomy for GD during the period 2006 to 2011 were included. As controls, 399 asymptomatic subjects without gallstones or previous cholecystectomy were included. Asymptomatic subjects were recruited from preventive medical consultations and were matched with cases for age, sex, and BMI.

The study was approved by the Human Subjects Committee of The Medica Sur Clinic and Foundation as conforming to the ethical guidelines of the 1975 Declaration of Helsinki.

Physical examination

Body weight was measured, in light clothing and without shoes, to the nearest 0.10 kg. Height was measured to the nearest 0.5 cm. BMI was calculated as weight (kg) divided by height (m) squared. Overweight was defined as a BMI ranging from 25 to 29.9 kg/m2 and obesity was defined when BMI > 30 kg/m2. Waist circumference (to the nearest 0.1 cm) was measured at the midpoint between the lower border of the rib cage and the iliac crest, and hip circumference was similarly obtained at the widest point between hip and buttock. Three blood pressure (BP) readings were obtained at 1 min intervals, and the second and third systolic and diastolic pressure readings were averaged and used in the analyses.

Analytical procedures

Plasma glucose and liver function of subjects in the fasting state was measured in duplicate using an automated analyser. The coefficient of variation for a single determination was 1.5%. Cholesterol, high-density lipoprotein (HDL)-cholesterol and triglyceride concentrations were measured by enzymatic colorimetric methods, using CHOL, HDL-C plus (second generation) and triglyceride assays, respectively, from Roche Diagnostics Co (Indianapolis, IN, USA). Low-density lipoprotein (LDL)-cholesterol concentrations were calculated using the Friedewald formula.13

Cardiovascular risk

CVD risk factors were defined as:

  • Overweight and obesity (BMI > 25 kg/m2 and > 30 kg/m2 respectively).

  • Hypertension (BP > 140/90 mmHg or use of antihypertensive medication).

  • Low HDL-cholesterol (< 1.0 mmol/L in men and < 1.3 mmol/L in women).

  • High LDL-cholesterol (> 4.3 mol/L).

  • High triglycerides (> 2.3 mmol/L), or T2DM (use of diabetes medication or reported physician diagnosis).

Statistical analysis

Means and standard deviations were used to describe the distributions of continuous variables in comparisons between healthy and cholecystectomy subjects. The non-parametric Mann-Whitney U test was applied because of the non-normal distribution of some of these variables. By means of cross-tabulations, the risks associated with the probability of having risk factors for CVD were estimated. Odds ratios (ORs) were calculated with the independent variables coded in a binary form. Statistical significance was determined by Fisher’s exact test (two-tailed) and 95% confidence intervals (CIs). To derive adjusted OR (adjusted for confounders) associated with the probability of risk factors for CVD, multivariate unconditional logistic regression analyses were conducted. Multicollinearity in the adjusted models was tested by deriving the covariance matrix. All statistical analyses were conducted using the statistics program SPSS/PC version 12.0 (SPSS, Chicago, IL, USA).

Results

Seven hundred and ninety-eight subjects were included, 399 who underwent cholecystectomy in the case group, and 399 controls. There were no significant differences between the groups in age (44 ± 14 vs. 43 ± 11 years, p = 0.08), sex (female 66 vs. 60%, p = 0.09), or BMI (26.6 ± 4.4 vs. 26 ± 4.6, p = 0.06). Those patients undergoing cholecystectomy had higher systolic (117 ± 12 vs. 112 ± 14 mmHg, p < 0.001) but not diastolic BP. They also had higher levels of fasting glucose (114 ± 38 vs. 92 ± 14 mg/ dL, p < 0.001), triglycerides (166 ± 114 vs. 152 ± 90 mg/dL, p = 0.04), and total cholesterol (203 ± 41 vs. 181 ± 47 mg/dL, p < 0.001). Similar differences were observed for cholesterol lipoproteins (Table 1).

Table 1.

Characteristics of patients undergoing cholecystectomy and healthy controls.

Variable  Cholecystectomy group (n = 399)  Healthy controls (n = 399)  P value 
Age (years)  44.6 ± 14.9  43 ± 11.1  0.08 
Female  266 (66%%)  242 (61%)  0.10 
Weight (kg)  71.4 ± 14.6  71 ± 14.1  0.69 
Height (cm)  163 ± 8.8  163 ± 13  0.99 
BMI (kg/m226.6 ± 4.4  26 ± 4.6  0.06 
Systolic blood pressure (mmHg)  117 ± 11.7  112 ± 13.6  < 0.0001 
Diastolic blood pressure (mmHg)  73.6 ± 8.4  73 ± 9.5  0.34 
Glucose (mg/dL)  114 ± 38  92 ± 14  < 0.0001 
Total cholesterol (mg/dL)  203 ± 41  181 ± 47  < 0.0001 
LDL-cholesterol (mg/dL)  127 ± 34  101 ± 40  < 0.0001 
HDL-cholesterol (mg/dL)  47 ± 14  55 ± 37  < 0.0001 
Triglycerides (mg/dL)  166 ± 114  152 ± 90  0.04 
ALT (U/L)  120 ± 211  28 ± 12  < 0.0001 
AST (U/L)  107 ± 200  31 ± 19  < 0.0001 

The case group had a higher prevalence of T2DM (7.2 vs. 3.2%, p = 0.01), high BP (13.2 vs. 3%, p ≤ 0.0001), and dyslipidaemia (7.7 vs. 3%, p = 0.004). The prevalence of a history of myocardial infarction did not differ between the groups (2.7 vs. 3.7%, p = 0.55) (Table 2).

Table 2.

Risk factors and previous history of cardiovascular disease.

Variable  Cholecystectomy group (n = 399)  Healthy controls (n = 399)  P value 
Type 2 diabetes mellitus  29 (7.2%)  13 (3.2%)  0.01 
High blood pressure  53 (13.2%)  12 (3%)  <0.0001 
Dyslipidaemia  31 (7.7%)  12 (3%)  0.004 
Cerebrovascular disease  3 (0.75%)  1 (0.25%)  0.62 
Myocardial infarction  11 (2.75%)  15 (3.75%)  0.55 

Univariate analysis demonstrated that patients undergoing cholecystectomy had increased risk of T2DM (OR 2.3, 95% CI 1.19-4.5, p = 0.01), high BP (OR 4.9, 95% CI 2.5-9.3, p < 0.001), and dyslipidaemia (OR 2.1, 95% CI 1.3-5.3, p = 0.004). The risk of having any disease considered as a risk factor for CVD was also increased (OR 2.7, 95% CI 1.8-4.1, p = 0.001). In multivariate analysis (adjusted for age, sex, and BMI), the risk of T2DM (OR 2.2, 95% CI 1.1-4.5, p = 0.018), high BP (5.1, 95% CI 2.6-10.1, p = 0.001), and dyslipidaemia (OR 2.7, 95% CI 1.3-5.5, p = 0.004) remained higher (Table 3). There were no differences in the risk for acute myocardial infarction or cerebrovascular disease (data not shown).

Table 3.

Increased risk of cardiovascular disease risk factors in subjects undergoing cholecystectomy versus healthy controls.

Risk factor  OR (95% CI)  P value 
Univariate analysis     
Type 2 diabetes mellitus  2.3 (1.1-4.5)  0.01 
High blood pressure  4.9 (2.5-9.3)  < 0.001 
Dyslipidaemia  2.1 (1.3-5.3)  0.004 
Any risk factor  2.7 (1.8-4.1)  0.001 
Multivariate analysis*     
Type 2 diabetes mellitus  2.2 (1.1-4.5)  0.018 
High blood pressure  5.1 (2.6-10.1)  0.001 
Dyslipidaemia  2.7 (1.3-5.5)  0.004 
Any risk factor  2.8 (1.8-4.8)  0.001 
*

Adjusted for age, sex, and body mass index.

Discussion

GD and CVD are both prevalent health problems worldwide. The pathogenesis of both diseases is multifactorial, including environmental and genetic factors. One of the main shared physiopathological mechanisms of both diseases involves cholesterol accumulation. In cholelithiasis, the liver secretes bile supersaturated with cholesterol,2 while in CVD, including CHD, stroke, aortic atherosclerosis, and peripheral artery disease, the pathogenesis involves the accumulation of cholesterol in atheroma plaque.3

In this study we demonstrate an increased prevalence of risk factors for CVD in patients undergoing cholecystectomy. Although there was a trend towards association with differences in age, sex, and BMI, the increased prevalence of CVD risk factors remained after multivariate analysis. A recent necropsy study reported an association of gallstone disease with diabetes and with increased BMI, but not with cardiovascular disease.14 In the same study, BMI (in women) and increased age were important risk factors for GD. In our study these confounders were properly controlled, and we observed an increased prevalence of T2DM in patients undergoing cholecystectomy. In both studies, hard outcomes in terms of prevalence of confirmed CVD were not increased in the subjects with GD. In our study at least, this could be explained by the young age of our subjects and a sample size that was underpowered to assess this uncommon outcome in this age group. Relevant information from death certificate data in Sweden shows that 26% of the mortality in patients who underwent cholecystectomy for acute or chronic gallbladder disease was because of CVD.15 In the NHANES III, a prospective population-based sample, GD (gallstones or cholecystectomy) was associated with increased overall mortality. The prevalence of gallstones was 7.4% and of cholecystectomy 5.3%. During an 18-month follow-up, the overall allcause mortality was 16.5% and cardiovascular mortality 6.7%.8

Atherosclerosis is a slow progressive disease associated with metabolic syndrome, and is the main pathogenic mechanism of CVD, with high morbidity and mortality. GD, including patients having chole-cystectomy, may be considered as a risk factor for developing CVD. This is concordant with the previous data from asymptomatic GD that showed an increased incidence of CVD risk factors (metabolic syndrome)9 and with increased intima-media thickness.13

Conclusion

Patients undergoing cholecystectomy have a higher prevalence of risk factors for cardiovascular disease. This categorises an important segment of the population as high-risk.

Study Highlights

  • What is current knowledge. Patients with gallstone disease have an increased prevalence of metabolic syndrome.

    Gallstone disease is a factor for increased markers of cardiovascular disease.

  • What is new here. Patients undergoing chole-cystectomy have an increased prevalence of risk factors for cardiovascular disease.

    This increase is independent of classical confounders including age, sex, and body mass index.

    Cholecystectomy is an indicator of classic cardiovascular’s risk factors.

References
[1.]
Gonzalez-Perez A., Garcia Rodriguez L.A..
Gallbladder disease in the general population: association with cardiovascular morbidity and therapy.
Pharmacoepidemiol Drug Saf, 16 (2007), pp. 524-531
[2.]
Bortnichak E.A., Freeman DH Jr., Ostfeld A.M., et al.
The association between cholesterol cholelithiasis and coronary heart disease in Framingham, Massachusetts.
Am J Epidemiol, 121 (1985), pp. 19-30
[3.]
Lloyd-Jones D., Adams R., Carnethon M., et al.
Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
Circulation, 119 (2009), pp. 480-486
[4.]
Kozak L.J., Hall M.J., Owings M.F..
National Hospital Discharge Survey: 2000 annual summary with detailed diagnosis and procedure data. Vital and health statistics.
Series 13, Data from the National Health Survey, (2002), pp. 1-194
[5.]
Bennion L.J., Grundy S.M..
Risk factors for the development of cholelithiasis in man (second of two parts).
New Engl J Med, 299 (1978), pp. 1221-1227
[6.]
Bennion L.J., Grundy S.M..
Risk factors for the development of cholelithiasis in man (first of two parts).
New Engl J Med, 299 (1978), pp. 1161-1167
[7.]
Mendez-Sanchez N., Chavez-Tapia N.C., Uribe M..
The role of dietary fats in the pathogenesis of gallstones.
Front Biosci, 8 (2003), pp. e420-e427
[8.]
Ruhl C.E., Everhart J.E..
Gallstone disease is associated with increased mortality in the United States.
Gastroenterology, 140 (2011), pp. 508-516
[9.]
Mendez-Sanchez N., Bahena-Aponte J., Chavez-Tapia N.C., et al.
Strong association between gallstones and cardiovascular disease.
Am J Gastroenterol, 100 (2005), pp. 827-830
[10.]
Mendez-Sanchez N., Zamora-Valdes D., Flores-Rangel J.A., et al.
Gallstones are associated with carotid atherosclerosis.
Liv Int, 28 (2008), pp. 402-406
[11.]
Wysowski D.K., Goldberg E.L., Comstock G.W., et al.
A study of a possible association between breast cancer and gallbladder disease.
Am J Epidemiol, 123 (1986), pp. 532-543
[12.]
Cho J.Y., Han H.S., Yoon Y.S., et al.
Risk factors for acute cholecystitis and a complicated clinical course in patients with symptomatic cholelithiasis.
Arch Surg, 145 (2010), pp. 329-333
[13.]
Friedewald W.T., Levy R.I., Fredrickson D.S..
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
Clin Chem, 18 (1972), pp. 499-502
[14.]
Khan H.N., Harrison M., Bassett E.E., et al.
A 10-year follow-up of a longitudinal study of gallstone prevalence at necropsy in South East England.
Dig Dis Sci, 54 (2009), pp. 2736-2741
[15.]
Nilsson E., Fored C.M., Granath F., et al.
Cholecystectomy in Sweden 1987-99: a nationwide study of mortality and preoperative admissions.
Scand J Gastroenterol, 40 (2005), pp. 1478-1485
Copyright © 2012. Fundación Clínica Médica Sur, A.C.
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2023.101138
No mostrar más